{'fraction_non_alphanumeric': 0.022962962962962963, 'fraction_numerical': 0.0, 'mean_word_length': 5.283720930232558, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing.

Application of molecular techniques to study the genetics and gene expression alterations in non-Hodgkin lymphomas (NHLs) has revealed examples of common genetic events shared across individual disease types as well as extensive heterogeneity within specific diseases. For example, diffuse large B-cell lymphoma (DLBCL) can be effectively divided into two broad molecular subgroups in which genetic changes unique to each subgroup continue to be further determined. The broad availability of next-generation sequencing (NGS) now affords the ability to fully characterize the genetics of individual tumor types and application of this to some common NHLs has provided a wealth of new information. NGS-based research in NHL has unraveled a complex set of genetic alterations that underlie each of the DLBCL molecular subgroups. For example, these and studies of other NHLs have indicated a variety of mechanisms by which nuclear factor- κB (NF-κB) is deregulated in mature B-cell neoplasms and have also found extensive common features between germinal center B-cell-like DLBCL and other germinal center-derived lymphomas. Overall, NGS has identified new players in each of the studied diseases and provided promising new therapeutic targets for NHL.